[KEI recommendations to WHO on COVID-related research]

“The WHO secretariat should request in writing that the funders of COVID-19 R&D including in particular governments and philanthropies include language in contracts and use their financial leverage to enable sharing of know-how, cell lines and rights in data and patents, for COVID-19 related technologies.

The WHO secretariat should request in writing that the funders of COVID-19 R&D including in particular governments and philanthropies include language in contracts and use their financial leverage to enable sharing of know-how, cell lines and rights in data and patents, for COVID-19 related technologies.

There should be no monopolies on patents, regulatory exclusivities, data or know-how in this pandemic. All relevant technology for COVID-19 products should be available either free or openly licensed with non-discriminatory, reasonable and affordable royalties….”